Want to see BBOT full AI Analyst Report?
Top Page
BridgeBio Oncology Therapeutics
(NASDAQ:BBOT)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.50
▼(-73.32% Downside)
Action:Reiterated
Date:10/08/26
The score is held down primarily by weak operating fundamentals (no revenue, widening losses, and worsening cash burn) and a strongly bearish technical setup (price below all key moving averages with negative MACD). A low-debt, equity-supported balance sheet provides some offset, but valuation is not meaningfully supportive given negative earnings and no dividend yield.
Positive Factors
Low leverage
Very low leverage limits interest obligations and reduces dependence on creditors while BBOT funds oncology development. This gives management greater flexibility to use capital for research and operations, although it does not eliminate the need for future financing.
Negative Factors
No revenue
With no reported revenue, BBOT has not yet demonstrated commercial product traction or an operating stream capable of funding research and development. The company therefore remains dependent on capital markets or other financing until its oncology programs generate sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage limits interest obligations and reduces dependence on creditors while BBOT funds oncology development. This gives management greater flexibility to use capital for research and operations, although it does not eliminate the need for future financing.
Read all positive factors
BridgeBio Oncology Therapeutics (BBOT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$218.07M
Dividend YieldN/A
Average Volume (3M)742.91K
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue GrowthN/A
EPS Growth-614363.93%
CountryUS
Employees88
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1232.82
Shares Outstanding80,174,270
10 Day Avg. Volume485,104
30 Day Avg. Volume742,915
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-3.41
Enterprise Value/Market Cap-1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.20K
Enterprise Value/Ebitda1.14
Forecast
1Y Price Target
$19.63Price Target Upside109.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
BridgeBio Oncology Therapeutics Business Overview & Revenue Model
Company Description
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States....
BridgeBio Oncology Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
70
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -186.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -194.47M | -145.21M | -80.66M | -64.68M | 0.00 | -43.36K |
| Net Income | -182.11M | -134.04M | -74.28M | -64.70M | -3.52K | -43.36K |
Balance Sheet | ||||||
| Total Assets | 376.71M | 448.38M | 194.42M | 332.89K | 144.58K | 144.28K |
| Cash, Cash Equivalents and Short-Term Investments | 225.71M | 425.46M | 1.70M | 0.00 | 0.00 | 0.00 |
| Total Debt | 2.51M | 2.77M | 0.00 | 70.09K | 43.11K | 36.96K |
| Total Liabilities | 53.59M | 37.28M | 5.71M | 396.46K | 166.46K | 162.64K |
| Stockholders Equity | 323.11M | 411.10M | 188.72M | -63.57K | -21.88K | -18.36K |
Cash Flow | ||||||
| Free Cash Flow | -193.82M | -114.50M | -763.82K | -52.49M | 0.00 | 0.00 |
| Operating Cash Flow | -193.14M | -113.89M | -763.82K | -52.08M | 0.00 | 0.00 |
| Investing Cash Flow | -166.35M | 73.33M | -184.00M | -2.82M | 0.00 | 0.00 |
| Financing Cash Flow | 383.73M | 383.40M | 186.46M | 55.12M | 0.00 | 0.00 |
BridgeBio Oncology Therapeutics Technical Analysis
Negative
9.37
Price Trends
5.78
Negative
7.02
Negative
8.43
Negative
Market Momentum
-0.79
Negative
22.09
Positive
10.55
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBOT, the sentiment is Negative. The current price of 9.37 is above the 20-day moving average (MA) of 3.34, above the 50-day MA of 5.78, and above the 200-day MA of 8.43, indicating a bearish trend. The MACD of -0.79 indicates Negative momentum. The RSI at 22.09 is Positive, neither overbought nor oversold. The STOCH value of 10.55 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BBOT.
BridgeBio Oncology Therapeutics Risk Analysis
BridgeBio Oncology Therapeutics disclosed 95 risk factors in its most recent earnings report. BridgeBio Oncology Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BridgeBio Oncology Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $555.43M | 20.33 | 20.85% | ― | -2.86% | -46.26% | |
58 Neutral | $887.83M | -2.93 | -207.18% | ― | -7.27% | -48.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $388.76M | -3.17 | -45.45% | ― | 2.33% | 36.86% | |
46 Neutral | $226.27M | -0.96 | -87.95% | ― | -100.00% | 14.08% | |
44 Neutral | $546.93M | -5.33 | -38.46% | ― | -87.03% | -179.91% | |
42 Neutral | $218.07M | >-0.01 | -46.90% | ― | ― | -614363.93% |
* Healthcare Sector Average
BBOT
BridgeBio Oncology Therapeutics
2.85
-8.02
-73.78%
PBYI
Puma Biotechnology
11.26
6.22
123.41%
CTMX
CytomX Therapeutics
2.44
-0.86
-26.06%
KURA
Kura Oncology
9.86
0.76
8.35%
ZNTL
Zentalis Pharmaceuticals
2.41
0.77
46.95%
CCCC
C4 Therapeutics
3.18
0.80
33.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.